
Watch our interview with CEO, Bernard Tourillon.
Watch our interview with CEO, Bernard Tourillon.
VANCOUVER , BC and ERIE, Pa., Nov. 20, 2020 – ImagineAR (CSE: IP) (OTCQB: IPNFF) an Augmented Reality Company that enables sports teams, brands and businesses to instantly create their own mobile phone AR campaigns, is pleased to announce that it will work with Shoppers Drug Mart and the event production agency HUMANCONTACT Inc., to deliver an Immersive AR Experience to over 2500 Corporate Staff, Pharmacist-Owners, and Front Store Managers across Canada. Using the ImagineAR Custom White-label mobile app, Shoppers Drug Mart will integrate dynamic AR into the live streamed virtual event sessions.
Karen Bossin , Director, Conferences & Events at Shoppers Drug Mart said; “We are excited to integrate ImagineAR into the launch of our 2021 Virtual Conferences, including on-screen live-streamed AR activations as well as real-time Immersive AR delivered into the homes of our attendees all across Canada . Shoppers Drug Mart is thrilled to be the global pioneer in integrating mobile augmented reality with virtual events.”
Gareth Musico , President of HUMANCONTACT, stated “Our approach to virtual events has been to re-imagine the traditional video call or stream experience and deliver engaging, interactive, and customized content to attendees at home. ImagineAR is an extension of this mission and we’re excited to utilize its capabilities for virtual events and conferences.”
“To be selected by Shoppers Drug Mart for their company-wide events validates ImagineAR is the leading AR immersive platform available today,” said Alen Paul Silverrstieen, CEO and President of Imagine AR. “With the success of this interactive program, we expect to aggressively market our AR Immersive Event Solution to retail companies around the globe.”
This press release is available on the Company’s AGORACOM Discussion Forum , a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.
About HUMANCONTACT Inc.
HUMANCONTACT is the most versatile creative agency of its kind. They are proud to offer clients an unrivaled breadth of capabilities and expertise, always delivered with the personalized service and strategic touch that sets them apart.
Core services include strategy & consultation, event production, design & branding, communications, video production, web development, and more, but there is hardly anything that they can’t do. www.humancontact.com
About ImagineAR
ImagineAR Inc. (CSE: IP) (OTC: IPNFF) is an augmented reality (AR) platform, ImagineAR.com, that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage videos, information, advertisements, coupons, 3D holograms and any interactive content all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The AR Enterprise platform supports both IOS and Android mobile devices and upcoming wearable technologies.
All trademarks of the property of respective owners.
ON BEHALF OF THE BOARD
Alen Paul Silverrstieen
President & CEO
(818) 850-2490
https://twitter.com/IPtechAR
https://www.facebook.com/imaginationparktechnologies
https://www.instagram.com/iptechar
https://www.linkedin.com/company/imagination-park-technologies-inc
We encourage you to do your own due diligence and ask your broker if Imagine AR Inc. (cse: IP) is suitable for your particular investment portfolio*.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward- looking information is based on certain key expectations and assumptions made by ImagineAR management. Although Imagine AR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Imagine AR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and Imagine AR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Advances Its Silicon Materials for Batteries Development Program
MONTREAL, Nov. 19, 2020 – Innovative silicon solutions provider HPQ Silicon Resources Inc. (“HPQ” or “the Company”) ( TSX-V: HPQ ; FWB: UGE ; Other OTC : URAGF ), is pleased to announce that, in addition to manufacturing samples of porous Silicon nanopowders of different sizes (2 nm to 1 µm) and pore structures (Microporous (<5nm), Mesoporous (5nm – 50nm) or Macroporous (>50nm)), HPQ Silicon R&D consortium member Apollon Solar of France has also commenced evaluation of different carbon encapsulating processes for Silicon nanopowders. As part of this HPQ – led effort, Apollon has delivered a first batch of carbon coated nano silicon powders to Professor Lionel Roué team at the Institut National de la Recherche Scientifique (INRS) for evaluation. Other batches of silicon materials (coated and non-coated) are being prepared and will be sent the INRS for evaluations over the coming weeks.
ACCELERATING R&D ON NANO SILICON POWDERS CARBON COATING
Apollon proposed that in addition to carbon coating their porous Silicon nanopowders they could use commercially available but expensive (US$ 22,500 per Kg) 1 nano silicon powders to evaluate the efficiency of different carbon coating processes. Using powders with the same characteristic as the powders to be produced by HPQ NANO PUREVAP™ N ANO S ILICON R EACTOR should reduce our R&D timeline and give us valuable insight moving forward.
“ Producing carbon coated nano silicon powders for testing this early in the process is another demonstration of the depth and flexibility of HPQ’s R&D consortium. HPQ is committed to staying at the forefront of Silicon for batteries R&D . This latest effort is part of our plan to produce products for renewable energy storage participants and electric vehicle manufacturers who continue to search for cost effective ways of increasing the Silicon contained in their batteries. ,” said Bernard Tourillon, President and CEO HPQ Silicon. “Silicon’s potential to meet energy storage demand is undeniable , generating massive investments , and serious industry interest. We are very confident that demand for the Silicon materials we will produce , with our low-cost scalable process es , will be high demand by batteries and EV manufacturers in this renewable energy revolution . ”
SILICON POTENTIAL FOR BATTERY ANODE MATERIAL BECOMES MAINSTREAM
Tesla’s latest battery day presentation confirmed that the future of battery anodes will include Silicon. Tesla’s “… plans on removing graphite from the anode … ” 2 , points to the need for innovative silicon solutions which HPQ is focused on, to make Silicon – based anodes technically and economically feasible for the production of more efficient rechargeable Li-batteries.
Presently, Silicon is used in a blended form with graphite and typically only represents around 5% by wt , which explains the limited performance improvements achieved to date. The primary hurdle to increasing Silicon anode content in Li-ion batteries is the mitigation of Silicon swelling and cracking during the lithiation phase 3 in order to achieve a cycling stability comparable to graphite.
Ongoing R&D indicates that the two most promising avenues for resolving these issues are:
HPQ is in the forefront of addressing these issues with the PUREVAP™ NSiR process and our ongoing work on porous silicon nanopowders and carbon coating nano silicon.
About HPQ Silicon
HPQ Silicon Resources Inc. ( TSX-V: HPQ ) is a Canadian Innovative Silicon Solutions Provider.
Silicon (Si), also known as silicon metal, is one of today’s key strategic materials needed for the decarbonization of the economy and the Renewable Energy Revolution (“RER”).
Silicon is the most abundant element in earth’s crust but does not exist in its pure state and must be extracted from quartz (SiO 2 ) in what has historically been a capital and energy intensive process. HPQ is building a portfolio of silicon–based products using innovative scalable processes. The target objective is to produce high value speciality Silicon products using technologies that will reduce energy consumption, GHG’s, and carbon footprint.
Working with PyroGenesis Canada Inc. (TSX-V: PYR) , a high-tech company that designs, develops, manufactures and commercializes plasma – based processes, HPQ is developing:
HPQ is also working with industry leader Apollon Solar of France to:
This News Release is available on the company’s CEO Verified Discussion Forum , a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.
Disclaimers:
The Corporation’s interest in developing the PUREVAP™ QRR and any projected capital or operating cost savings associated with its development should not be construed as being related to the establishing the economic viability or technical feasibility of any of the Company’s Quartz Projects.
This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s on-going filings with the security’s regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information contact
Bernard J. Tourillon, Chairman, President and CEO Tel (514) 907-1011
Patrick Levasseur, Vice-President and COO Tel: (514) 262-9239
http://www.hpqsilicon.com Email: [email protected]
ThreeD Capital (IDK:CSE / IDKFF:OTCQB) prides itself on discovering great companies before everyone else … and it casts a wide net to find the best of the best ranging from precious metals companies to completely disruptive companies. Moreover, IDK isn’t afraid to invest and be patient in both public and private companies.
As such, it’s like and ETF for ground floor investments that small cap investors would either be unable to find (private) or unable to participate in (early round accredited investors)
It is able to do all this and do it well under the leadership of one of the greatest investors in Canadian history – Sheldon Inwentash, the Founder, Chairman and CEO of IDK. Inwentash’s track record of success speaks for itself, including successful exits in the hundreds of millions and even billions in previous years. His last company commanded a market cap north of $1 Billion and now he’s looking to create another success out of IDK.
Will he do it? He’s off to a good start so far by quietly making investments over the past couple of years that are now starting to pay off. In this interview Inwentash discusses:
Best of all, after one hell of a ride for the financial markets in 2020, Inwentash talks about why 2021 “is the year to be all in”
Watch this great interview … because when a legendary financier speaks, every small cap investor should be listening.
OAKLAND, CA and TORONTO, Nov. 18, 2020 /CNW/ – Harborside Inc. (“Harborside” or the “Company”) (CSE: HBOR) (OCTQX: HBORF), a California-focused, vertically integrated cannabis enterprise, today reported its financial results for the period ending September 30, 2020 (“Q3 2020”). The Q3 2020 financial report and corresponding management’s discussion and analysis (collectively the “Q3 Filings”) are available for download from the Company’s investor website,investharborside.com, and on the Company’sSEDAR profile. Unless otherwise indicated, all dollar amounts in this press release are in U.S. dollars.
Management Commentary
“We’ve implemented strong operational improvements that have continued our progress towards long term profitability and sustained growth. Harborside continues to be one of the leaders in the Northern California market,” said Peter Bilodeau, Chairman, and interim Chief Executive Officer. “As our production capacity is expected to ramp up in early 2021, following the completion of the planned upgrades at our Salinas greenhouse facility, we expect to be well-positioned to accelerate our growth and continue to gain wholesale market share. I’m thrilled with how far Harborside has come this year and look forward to further growth in 2021.”(2)
Q3 2020 Financial Results and Highlights (2)(3)
Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | |
Retail Revenues | $10,681,897 | $10,940,143 | $10,181,471 | $9,511,221 |
Wholesale Revenues(a) | $8,890,723 | $5,208,439 | $4,456,775 | $2,185,701 |
Total Gross Revenues(a) | $19,572,620 | $16,148,582 | $14,638,246 | $11,696,922 |
Retail Gross Profit(e) | $5,353,429 | $5,601,565 | $5,219,890 | $4,903,947 |
Wholesale Gross Profit(a)(e) | $5,360,764 | $2,435,952 | $787,964 | -$1,373,186 |
Total Gross Profit(a)(e) | $10,714,193 | $8,037,517 | $6,007,854 | $3,530,761 |
Retail Gross Margin(b)(e) | 50.10% | 51.20% | 51.30% | 51.60% |
Wholesale Gross Margin(a)(e) | 60.30% | 46.80% | 17.70% | -62.80% |
Total Gross Margin(e) | 54.70% | 49.80% | 41.00% | 30.20% |
G&A/Professional Fees(c)(d) | $6,783,987 | $6,764,781 | $5,786,573 | $7,621,971 |
Adjusted EBITDA(e) | $4,473,046 | $642,025 | $431,562 | -$2,796,178 |
NOTES: |
a. Not including excise taxes or biological asset adjustments. |
b. Retail gross margin in Q1 2020 and Q2 2020 are slightly affected by additional expenditures on personal protective equipment and other safety measures due to the COVID-19 pandemic. Retail gross margin in Q2 2020 and Q3 2020 include additional pay for the Company’s front line workers and expenses relating to the impacts of the civil unrest in the Bay Area to certain of the Company’s retail stores. |
c. Professional Fees for the fourth quarter of 2019 include approximately $953,000 in one-time fees and accruals for legal matters |
d. Professional Fees for Q2 2020 and Q3 2020 include approximately $977,000 and $1,115,000, respectively, in one-time costs relating to the audits and restatements of certain of the Company’s previous financial statements. |
e. This is a non-IFRS reporting measure. For a reconciliation of this to the nearest IFRS measure, see “Use of Non-IFRS Measures” and “Non-IFRS Measures” in the Company’s management discussion and analysis for September 30, 2020. |
Q3 2020 Financial Summary
During Q3 2020, Harborside generated total gross revenues of approximately $19.6 million. This represented 21.2% sequential growth over the second quarter of 2020 (“Q2 2020”) and a 42.9% year-over-year increase when compared to the approximately $13.7 million of gross revenues reported in the period ending September 30, 2019 (“Q3 2019”). Combined gross profit before excise taxes and adjustments for biological assets was approximately $10.7 million, an 85.8% year-over-year increase as compared to the $5.8 million reported in Q3 2019. On a year over year basis, combined gross margins increased from 42.1% in Q3 2019 to 54.7% in Q3 2020(1).
Harborside’s wholesale operations reported gross wholesale revenues of approximately $8.9 million, representing 70.7% sequential growth compared to Q2 2020 and a year-over-year increase of 169.4% as compared to the approximately $3.3 million in gross revenues reported for Q3 2019. The year-over-year increase in gross wholesale revenues was primarily due to improved harvest yields and production of premium flower, higher sales volumes, and higher average prices per pound at the Company’s 47-acre integrated production campus in Salinas, California (the “Salinas Facility”). As compared to gross wholesale revenues, wholesale gross margins increased from -22.1% in Q3 2019 to 60.3% in Q3 2020(1).
The Company’s retail operations generated revenues of approximately $10.7 million, a 2.8% increase as compared to the approximately $10.4 million realized in Q3 2019, with gross margins improving from 48.5% to 50.1% on a year-over-year basis, despite increased costs for safety and staffing related to COVID-19 and inventory losses experienced during the civil unrest that occurred in the Bay Area.(1) The year-over-year increase in retail revenue was driven primarily by the Company’s enhanced merchandising and pricing initiatives which resulted in, amongst other things, improved product mix, selected pricing changes and higher sell-through of internally produced products. Across Harborside’s retail stores in California, the Company’s branded products represented from 9 to 14 of the 25 top-selling SKUs in Q3 2020.
Total operating expenses for Q3 2020 were approximately $7.8 million, including $1.15 million in one-time costs related to the audit and restatement of prior year financials. This was a 7.5% year-over-year decrease when compared to approximately $8.5 million of costs incurred in Q3 2019. The year-over-year decrease in operating expenses is primarily related to a decrease in general and administrative expenses of $1.1 million to $4.1 million as compared to $5.2 million in Q3 2019, a decrease in allowance for credit losses of $0.3 million, and a decrease in write-downs of receivables, investments and advances of $1.3 million, as no impairments were recorded on any of the Company’s investments in Q3 2020.
During Q3 2020, the Company also recorded an income tax provision of $1.8 million, compared to $1.3 million in Q3 2019, based on estimated federal income taxes payable at period-end.
Operating Income for Q3 2020 was approximately $0.8 million, compared to an operating loss of approximately $3.6 million for Q3 2019. Net loss and comprehensive loss was $2.4 million, compared to a net loss and comprehensive loss of $1.9 million in Q3 2019, a 24.2% decrease on a year-over-year basis. The year over year decrease was due primarily to additional income tax provisions and related interest expense booked during Q3 2020.
Adjusted EBITDA(1) for Q3 2020 was approximately $4.5 million, compared to a negative EBITDA(1) of approximately $0.9 million for Q3 2019, with the year over year increase being driven largely by improved operating efficiencies and headcount reductions across the Company. See “Non-IFRS Financial Measures, Reconciliation, and Discussion.”
Q4 2020 and Full Year Expectations (2)(4)
The Company expects Q4 2020 gross revenues to follow a more historically typical seasonal pattern, with lower flower production and wholesale revenues, resulting in total combined gross revenues of $11 million to $12.5 million for the fourth quarter, with EBITDA(1) for the quarter close to breakeven. For the full year ended December 31, 2020, the Company expects gross revenues in the range of approximately $61 – $63 million, with Adjusted EBITDA(1) for the year in the range of 8 – 10% of revenues.
Liquidity and Cash Balance (2)(3)
As of September 30, 2020, Harborside had approximately $13.3 million in cash. The increase in cash balance since the second quarter of 2020 included a delay in payment of approximately $1.6 million of sales taxes that were due to the state of California. Payment of these taxes was postponed by the state as part of their COVID-19 business relief program and, in accordance with state guidelines, the funds were ultimately remitted at the end of October 2020.
Recent Operational Highlights
Wholesale Operations: Harborside recently announced planned cultivation facility upgrades at the Salinas Facility. The planned upgrades include, among other things, the installation of blackout curtains and supplemental LED grow lights at the Salinas Facility. Following the successful completion of these upgrades, the Company expects an approximately 50% increase in production, an expected approximately 10% increase in bulk wholesale revenue capacity, and an approximately 7% increase in the total productive capacity, on an annualized basis(2)(4). The upgrades are expected to be completed within the first quarter of 2021(2).
In furtherance of its brand strategies, Harborside announced that two of its award-winning in-house brands, Harborside Farms and Key, introduced new product offerings for the market. Key has added ‘Key Mini Pre-Rolls’, a pack of seven 0.5g strain specific pre-rolls, to its product suite. These mini pre-rolls use flower that is sustainably grown in Harborside’s state of the art greenhouses using proprietary techniques. Key also recently offered a new seasonal SKU, ‘Limited Edition Skeleton Key Mini Pre-Rolls’, a nighttime blend of G4 OG and Gelato 33 packed in seven 0.5g mini pre-rolls. Harborside Farms has also added ‘Harborside Farms Quarter Ounces’, which offers strain-specific and single-origin flower from Harborside Farms. The Company also recently commenced sales of clones grown at its Salinas Facility at all Harborside branded retail locations, including Desert Hot Springs.
Capital Markets: During Q3 2020, the Company commenced trading on the OTCQX under the ticker symbol of “HBORF” and, subsequent to the quarter end, Harborside received depository trade clearance (DTC) eligibility.
Acquisitions: Subsequent to Q3 2020, Harborside announced it had executed a definitive agreement with FGW Haight, Inc. (“FGW”) to acquire majority ownership FGW, which holds a dispensary license in the historic Haight-Ashbury District of San Francisco, where the Company expects to start operations in the second quarter of 2021(2).
Secured Indemnity
On November 17, 2020, the Company and its subsidiaries entered into a guaranty and security agreement to guarantee and secure the obligations of the Company to defend and to indemnify its directors and officers (collectively, the “Secured Indemnity“). The Secured Indemnity is intended to supplement coverage available under existing directors and officers insurance maintained by the Company in order to mitigate concerns about claims and potential claims against directors and officers and whether the available insurance applies to and will satisfy in full such claims and potential claims. The scale and complexity of the Company’s operations in a highly regulated sector requires that the directors and officers managing those operations be committed to the performance of their duties without undue or inappropriate distractions. In management’s view, concerns about claims and potential claims and adequacy of insurance may detract from the performance of the directors and officers involved in the Company’s operations or lead to their resignations, which would disrupt the Company’s business. The Board has therefore determined that it is in the best interests of the Company and its subsidiaries to enter into the Secured Indemnity in order to induce the directors and officers to perform their duties to the Company, provide comfort to the directors and officers involved in the Company’s operations and to encourage their ongoing services.
The Secured Indemnity constitutes a “related party transaction” under Multilateral Instrument 61-101 – Protection of Minority Securityholders in Special Transactions (“MI 61-101“). The Company is relying on the exemptions from the valuation and the minority approval requirements of MI 61-101 provided for in subsections 5.5(a) and 5.5 (b) and subsection 5.7(a) of MI 61-101, respectively, as the Company’s shares are not listed on specified markets and neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the Secured Indemnity, in relation to the interested parties, will represent more than 25% of the Company’s market capitalization, as determined in accordance with MI 61-101.
For the latest news, activities, and media coverage, please visit the Harborside corporate website athttp://www.investharborside.com or connect with us onLinkedIn,Facebook, andTwitter.
About Harborside:
Harborside Inc., a vertically integrated enterprise with cannabis licenses covering retail, distribution, cultivation, nursery, and manufacturing, is one of the oldest and most respected cannabis companies in the world. Founded in California in 2006, Harborside was awarded one of the first six medical cannabis licenses granted in the United States. Today, the company operates three major dispensaries in the San Francisco Bay Area, a dispensary in the Palm Springs area outfitted with Southern California’s only cannabis drive-thru window, a dispensary in Oregon and an integrated cultivation/production facility in Salinas, California. Harborside continues to play an instrumental role in making cannabis safe and accessible to a broad and diverse community of California and Oregon consumers. Harborside is currently a publicly listed company, trading on the CSE under the ticker symbol “HBOR” and the OTCQX under the ticker symbol “HBORF”. Additional information regarding Harborside is available under Harborside’s SEDAR profile atwww.sedar.com.
Safe Space Technology™
TORONTO, ON / November 18, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to provide an update on its BioCloud technology development.
“Our team continues to execute on the vision to create and bring to market a safe space technology,” says Paul Ghezzi, CEO of Kontrol.
Distribution Agreements
The Company intends to sell BioCloud directly to various potential customers. At the same time the Company is pursuing both exclusive and non-exclusive distribution channels for BioCloud sales. Kontrol is pleased to announce it has entered into two non-exclusive BioCloud distribution agreements. The distribution agreements cover Ontario and Saskatchewan.
The Company has also entered into discussions with various parties for potential industry exclusive distribution agreements which would require minimum unit quantity orders.
New Website
Kontrol has launched a new website for BioCloud. For more information please visit www.kontrolbiocloud.com.
Name Change
Kontrol Energy Corp. is in the process of changing its name to Kontrol Technologies Inc. The name change is anticipated to take place by the end of December 2020.
Cash on Hand
As of November 17, 2020, the Company has $3.8 Million of cash on hand.
About Kontrol BioCloud
BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others
BioCloud is not a medical device and the Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).
About Kontrol Energy
Kontrol Energy Corp. (CSE:KNR)(OTCQB: KNRLF)(FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.
Kontrol Energy is one of Canada’s fastest growing companies in 2018 and 2019 as ranked by Canadian Business and Maclean’s.
![]() | ![]() |
Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com.
For further information, contact:
Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123
Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.
Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
SOURCE: Kontrol Energy Corp.
TORONTO, ON and NEW YORK, NY / November 17, 2020 / Binovi Technologies Corp., (Binovi) (TSXV:VISN)(OTCQB:BNVIF), a leader in neuro-vision performance technology, is pleased to announce it has closed its previously announced non-brokered private placement financing for gross proceeds of $2,050,000 (the “Private Placement”). The Company issued a total of 16,078,431 units at $0.1275 per unit, with each unit comprised of one common share of the Company (a “Share”) and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Share (each, a “Warrant Share”) at an exercise price of $0.40 per Warrant Share at any time until November 16, 2022. The warrants are subject to an acceleration clause whereby if the common share price is equal to or greater than $0.45 for a period of 5 consecutive trading days (at any time at or following the expiry of the four months resale restriction period), the Company may, by notice to the warrant holder reduce the remaining exercise period applicable to the warrants to not less than 30 days from the date of such notice.
The Company paid aggregate finder’s fees of $21,274.65 in cash and 166,860 finder’s warrants, with each finder warrant having the same terms as the Warrants.
The securities issued in connection with the Private Placement are subject to a four-month hold period expiring on March 18, 2021. Further restrictions may apply to certain subscribers under foreign securities laws.
Insiders participated in the Private Placement acquiring an aggregate of 2,284,314 units on the same basis as other subscribers. The participation in the Private Placement by insiders of the Company constitutes a “related party transaction” as such term is defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company is relying on exemptions from the formal valuation and minority approval requirements under MI 61-101. The Company relied on Section 5.5(a) of MI 61-101 for an exemption from the formal valuation requirement and Section 5.7(1)(a) of MI 61-101 for an exemption from the minority shareholder approval requirement of MI 61-101 as the fair market value of the private placement in so far as the private placement involved interested parties did not exceed 25% of the Company’s market capitalization.
The Company intends to use the net proceeds from the Private Placement for general working capital.
For additional information on the Company, please visit https://www.binovi.com/investor-reports/
About Binovi Technologies Corp.
Binovi is a best-in-class neuro-visual performance platform designed to test, analyze, track, and report on individual cognitive performance. Binovi combines hardware, software, specialized expert knowledge, and unique data insights to deliver customized, one-on-one training and learning protocols ideal for K-12 Students, Vision Care Specialists, and Sports Performance testing and training. Designed for vision optimization and the enhancement of skills related to cognitive performance, Binovi provides measurable results in less time, and with less effort. Binovi is currently used in over 20 countries.
Terry Booth
Executive Chairman
Adam Cegielski
Founder | CEO
Investor Relations
Email: [email protected]
Toll-free: 1 (844) 866-6162
Forward looking information:
Certain statements contained in this news release constitute “forward-looking information” as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company’s financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company’s financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company’s continuous disclosure filings filed under the Company’s profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
November 17, 2020 Toronto, New York – Binovi Technologies Corp., (Binovi) (TSXV:VISN ) ( OTC:BNVIF) is proud to announce the appointment of Dr. Susan Barry to the Binovi Scientific Advisory Board. Dr. Barry joins the other members of the board in directing the company’s advancements.
“Dr. Barry’s experiences as a patient of vision therapy have informed her extensive career and we hope to gain from her perspective on both sides of the vision care coin. Her work in the neurological examination of vision will prove incredibly valuable in our pursuit of further testing and treatment options for students and patients young and old,” commented Adam Cegielski, President and CEO.
“It is a distinct privilege to have Dr. Barry join our Scientific Advisory Board,” said Dr. Leonard Press, Chief Scientific Officer. “Her unique blend of insights and communication skills that crosses many lines between educators, eyecare professionals, researchers and the public is a tremendous asset to Binovi.”
” Children struggling in school, adults recovering from a stroke, and athletes seeking to improve their game may all benefit from vision therapy. Its effects are often life-changing. I am looking forward to working with the Binovi team to develop new training techniques, explore the science behind vision therapy, and make vision therapy more accessible worldwide,” commented Dr. Susan R Barry, Ph.D.
About Dr. Susan Barry
Susan R. Barry, Ph.D. is an educator, scientist, and author who has spoken worldwide on the topics of neuroplasticity and binocular vision. She earned her B.A. in biology from Wesleyan University in 1976 and Ph.D. in biology from Princeton University in 1981. She has worked as a research neuroscientist at the University of Miami Medical School, the University of Michigan, the Marine Biological Laboratory, and NASA’s Johnson Space Center and published papers on synaptic transmission and eye-head-hand coordination. In 1992, she joined the faculty of Mount Holyoke College where she rose to the rank of full professor, retiring from the college in 2016. The Princeton Review lists Barry among the 300 outstanding college teachers in the U.S., her paper on the work of Frederick W. Brock was selected as the best published paper in the Journal of Behavioral Optometry in 2011, and in 2013 she received the Meribeth E. Cameron Faculty Award for Scholarship from Mount Holyoke College.
For years, Barry taught her neurobiology students the conventional scientific wisdom that stereovision could develop only during a critical period in early childhood. She even used her own vision history to support this dogma since she had been cross-eyed since early infancy and was stereoblind. However, at age forty-eight, she consulted a developmental optometrist who prescribed a program of optometric vision therapy. To her utter astonishment, her vision improved dramatically, and she experienced her first 3D views. Dubbed “Stereo Sue” by Oliver Sacks in a 2006 New Yorker article by that name, Dr. Barry has gone on to write her own book Fixing My Gaze: A Scientist’s Journey into Seeing in Three Dimensions (Basic Books, 2009) which was rated the fourth best science book for 2009 by the editors of Amazon.com, selected as one of the best sci-tech books of 2009 by the Library Journal, and has been translated into seven languages. Barry’s second book, Coming to Our Senses: A Boy Who Learned to See, A Girl Who Learned to Hear, and How We All Discover the World , will be published by Basic Books in the summer of 2021.
For additional information on the Company, please visit https://www.binovi.com/investor-reports
About Binovi Technologies Corp.
Binovi is a best-in-class neuro-visual platform designed to test, analyze, track, and report on individual vision and cognitive performance. Binovi combines hardware, software, specialized expert knowledge, and unique data insights to deliver customized, one-on-one training and learning protocols ideal for K-12 Students, Sports Performance testing and training, and other areas of specialized care. Designed for vision optimization and the enhancement of skills related to cognitive performance, Binovi provides measurable results in less time, and with less effort. Binovi is currently used in over 1,500 locations across 20 countries.
Terry Booth
Executive Chairman
Adam Cegielski
Founder | CEO
Investor Relations
Email: [email protected]
Toll-free: 1 (844) 866-6162
Forward looking information:
Certain statements contained in this news release constitute “forward-looking information” as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company’s financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company’s financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company’s continuous disclosure filings filed under the Company’s profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.
Aras Azadian Chief Executive Officer and Co-Founder of Avicanna discusses the company’s medical cannabis which is trusted by physicians and clinicians. Azadian states, “Only 5% of physicians are currently prescribing Cannabis.” He continues to explain that the medical community has been skeptical of Canadian Licensed producers. Avicanna provides medical and only medical, this bodes well with the medical community.
TORONTO, ON / November 16, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) today announced that CEO Paul Ghezzi will present to investors at the Virtual Fall Investor Summit on Wednesday, November 18, 2020 at 4:00pm EDT. Participants can listen to Kontrol’s presentation at https://www.webcaster4.com/Webcast/Page/2038/38778. As facilitated by the conference, Kontrol will also participate in scheduled meetings.
“Kontrol Energy continues to build upon our base business that addresses the growing problem of energy waste, greenhouse gas emissions and air quality in the building sector,” said Mr. Ghezzi. “Kontrol has recently announced its plans to commercialize the Kontrol BioCloud analyzer (or BioCloud). BioCloud is a real-time viral detection technology. We look forward to connecting with the Virtual Fall Summit community.”
About Kontrol BioCloud
BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others. It can be an important technology which supports the entire system of individual testing and contact tracing.
Kontrol BioCloud is not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).
About Kontrol Energy
Kontrol Energy Corp. (CSE:KNR) (OTCQB:KNRLF) (FSE:1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.
Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at http://www.sedar.com.
For further information, contact:
Paul Ghezzi, Chief Executive Officer [email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123
Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.
Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
About the Fall Investor Summit Conference
The Fall Investor Summit will take place virtually, featuring 75 companies and over 300 institutional and retail investors.
The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.
To register as a presenting company: please contact Brittney Blocker ([email protected])
To request complimentary investor registration: please visit our website at www.investorsummitgroup.com
FOR MORE INFORMATION
Please visit: www.investorsummitgroup.com
Or, contact Brittney Blocker at [email protected]
News Compliments of ACCESSWIRE
SOURCE: Kontrol Energy Corp.